LONDON (Alliance News) - Faron Pharmaceuticals Oy is to target colorectal cancer in its upcoming test programme for Clevegen, it said Thursday.
The testing of Clevegen on patients with late-stage colorectal cancer will begin once the dosage has been confirmed.
Clevegen is an anti-clever 1 antibody, which causes changes in the immune environment of solid tumours.
Early data from an earlier stage of trials shows four patients dosed with Clevegen have showed a more active immune system.
Faron Chief Executive Markku Jalkanen said: "We are encouraged by the data gathered so far from the MATINS study, particularly the tumour imaging report from a colorectal patient in whom all other treatments have failed, which demonstrates a partial response according to RECIST already in nine weeks.
"This information further supports our belief Clevegen has the ability to function as a novel macrophage checkpoint immunotherapy for patients with currently untreatable solid cancers."
"Advancing MATINS into the cohort expansion stage later this year indicates our commitment to rapidly advance development of this potential therapy for patients in need of new treatment options," Jalkanen added.
Shares were 0.3% higher on Thursday at 59.70 pence each.
Faron Pharma (FARN)